Oxaliplatin Injection, Solution, Concentrate
Product Images NDC 16729-332

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 16729-332). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxaliplatin Injection, Usp 100 mg/20 mL (5 mg/ml)-single-dose Vial-carton (Oxaliplatin Inj 100mg 20ml Carton)

Carton label for Oxaliplatin Injection USP, 100 mg/20 mL (6 mg/mL) concentrate for intravenous use, single-dose vial. The label states sterile aqueous solution that is preservative free. It includes storage instructions, handling precautions, and warning that the product contains a cytotoxic agent. Manufactured by Accord Healthcare Inc. with NDC 16729-332.*

FDA Label Image

Oxaliplatin Injection, Usp 100 mg/20 mL (5 mg/ml)-single-dose Vial-label (Oxaliplatin Inj 100mg 20ml Label)

Label for Oxaliplatin Injection USP 100 mg/20 mL (5 mg/mL) concentrate for intravenous injection by Accord Healthcare Inc. The single-dose vial solution is preservative-free and contains 100 mg oxaliplatin per 20 mL. The label includes dosage instructions, storage conditions (20° to 25°C), and warnings to avoid mixing with sodium chloride or chloride-containing solutions. The product is Rx only and includes a barcode and lot/expiration placeholders.*

FDA Label Image

Oxaliplatin Injection, Usp 200 mg/40 mL (5 mg/ml)-single-dose Vial-carton (Oxaliplatin Inj 200mg 40ml Carton)

Label for Oxaliplatin Injection USP 200 mg/40 mL (5 mg/mL) concentrate, an intravenous sterile aqueous solution supplied in single-dose vials. Label states the product is preservative-free and intended for IV use only. Manufactured for Accord Healthcare Inc. and by Intas Pharmaceuticals Limited, India. Contains warnings about cytotoxic agent handling, storage instructions, and directions to avoid mixing with sodium chloride or chloride-containing solutions.*

FDA Label Image

Oxaliplatin Injection, Usp 200 mg/40 mL (5 mg/ml)-single-dose Vial-label (Oxaliplatin Inj 200mg 40ml Label)

Label for Oxaliplatin Injection USP 200 mg/40 mL (5 mg/mL) concentrate for intravenous use. This single-dose vial product is manufactured by Accord Healthcare Inc. The label includes storage instructions, warnings about cytotoxicity, and cautions against mixing with sodium chloride solutions. It also displays the NDC 16729-332 and barcode.*

FDA Label Image

Oxaliplatin Injection, Usp 50 mg/10 mL (5 mg/ml)-single-dose-carton (Oxaliplatin Inj 50mg 10ml Carton)

Packaging label for Oxaliplatin Injection USP 50 mg/10 mL (6 mg/mL) concentrate for intravenous use by Accord Healthcare Inc. The label states it is a sterile aqueous solution, preservative-free, single-dose vial for IV use only. Warnings include not to mix or add to sodium chloride or chloride-containing solutions. The label includes manufacturer details, storage instructions, and caution that it contains a cytotoxic agent.*

FDA Label Image

Oxaliplatin Injection, Usp 50 mg/10 mL (5 mg/ml)-single-dose Vial-label (Oxaliplatin Inj 50mg 10ml Label)

Label for Oxaliplatin Injection USP, 50 mg/10 mL (5 mg/mL) concentrate for intravenous injection. The single-dose vial contains sterile aqueous solution, preservative-free. The label includes storage instructions and warnings to avoid mixing with sodium chloride solutions. Manufactured by Accord Healthcare Inc. and Intas Pharmaceuticals.*

FDA Label Image

Figure 1 (Oxaliplatin Inj Figure 1)

A Kaplan-Meier survival curve comparing DFS probability over 72 months for two treatment arms: FOLFOX4 (solid line) and LV5FU2 (dashed line). It shows the number of patients at risk at various time points, the number of events with percentages, and statistical data including hazard ratio, confidence interval, and p-value from a stratified logrank test.*

FDA Label Image

Figure 2 (Oxaliplatin Inj Figure 2)

A line graph depicting Disease-Free Survival (DFS) Probability over time in months for two treatment arms in Stage III patients. The solid line represents FOLFOX4 - DUKES C treatment, and the dashed line represents LV5FU2 - DUKES C treatment. The graph includes hazard ratio and p-value statistics indicating comparative results.*

FDA Label Image

Figure 3 (Oxaliplatin Inj Figure 3)

A Kaplan-Meier survival curve chart comparing the percentage of patients surviving over 24 months for three treatment groups: Eloxatin plus 5-FU/LV, Eloxatin plus irinotecan, and Irinotecan plus 5-FU/LV. The chart shows median survival times in months for each group, with Eloxatin plus 5-FU/LV having the highest median survival. The x-axis represents months, and the y-axis represents percent of patients surviving.*

FDA Label Image

Chemical Structure (Oxaliplatin Inj Structure)

Chemical structure of oxaliplatin showing the platinum atom coordinated to a cyclohexane diamine group and oxalate ligand.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.